Cargando…

Human Immunodeficiency Virus, Antiretroviral Therapy and Markers of Lymphatic Filariasis Infection: A Cross-sectional Study in Rural Northern Malawi

BACKGROUND: Lymphatic filariasis (LF) and human immunodeficiency virus (HIV) are major public health problems. Individuals may be co-infected, raising the possibility of important interactions between these two pathogens with consequences for LF elimination through annual mass drug administration (M...

Descripción completa

Detalles Bibliográficos
Autores principales: Tafatatha, Terence, Taegtmeyer, Miriam, Ngwira, Bagrey, Phiri, Amos, Kondowe, Mariot, Piston, Wilson, Molesworth, Anna, Kayuni, Ndoliwe, Koole, Olivier, Crampin, Amelia, Horton, John, French, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456405/
https://www.ncbi.nlm.nih.gov/pubmed/26042839
http://dx.doi.org/10.1371/journal.pntd.0003825
_version_ 1782374835502972928
author Tafatatha, Terence
Taegtmeyer, Miriam
Ngwira, Bagrey
Phiri, Amos
Kondowe, Mariot
Piston, Wilson
Molesworth, Anna
Kayuni, Ndoliwe
Koole, Olivier
Crampin, Amelia
Horton, John
French, Neil
author_facet Tafatatha, Terence
Taegtmeyer, Miriam
Ngwira, Bagrey
Phiri, Amos
Kondowe, Mariot
Piston, Wilson
Molesworth, Anna
Kayuni, Ndoliwe
Koole, Olivier
Crampin, Amelia
Horton, John
French, Neil
author_sort Tafatatha, Terence
collection PubMed
description BACKGROUND: Lymphatic filariasis (LF) and human immunodeficiency virus (HIV) are major public health problems. Individuals may be co-infected, raising the possibility of important interactions between these two pathogens with consequences for LF elimination through annual mass drug administration (MDA). METHODOLOGY AND PRINCIPAL FINDINGS: We analysed circulating filarial antigenaemia (CFA) by HIV infection status among adults in two sites in northern Malawi, a region endemic for both LF and HIV. Stored blood samples and data from two geographically separate studies were used: one a recruitment phase of a clinical trial of anti-filarial agent dosing regimens, and the other a whole population annual HIV sero-survey. In study one, 1,851 consecutive adult volunteers were screened for HIV and LF infection. CFA prevalence was 25.4% (43/169) in HIV-positive and 23.6% (351/1487) in HIV-negative participants (p=0.57). Geometric mean CFA concentrations were 859 and 1660 antigen units per ml of blood (Ag/ml) respectively, geometric mean ratio (GMR) 0.85, 95%CI 0.49-1.50. In 7,863 adults in study two, CFA prevalence was 20.9% (86/411) in HIV-positive and 24.0% (1789/7452) in HIV–negative participants (p=0.15). Geometric mean CFA concentrations were 630 and 839 Ag/ml respectively (GMR 0.75, 95%CI 0.60-0.94). In the HIV-positive group, antiretroviral therapy (ART) use was associated with a lower CFA prevalence, 12.7% (18/142) vs. 25.3% (67/265), (OR 0.43, 95%CI 0.24-0.76). Prevalence of CFA decreased with duration of ART use, 15.2% 0-1 year (n=59), 13.6% >1-2 years (n=44), 10.0% >2-3 years (n=30) and 0% >3-4 years treatment (n=9), p<0.01 χ(2) for linear trend. CONCLUSIONS/SIGNIFICANCE: In this large cross-sectional study of two distinct LF-exposed populations, there is no evidence that HIV infection has an impact on LF epidemiology that will interfere with LF control measures. A significant association of ART use with lower CFA prevalence merits further investigation to understand this apparent beneficial impact of ART.
format Online
Article
Text
id pubmed-4456405
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44564052015-06-09 Human Immunodeficiency Virus, Antiretroviral Therapy and Markers of Lymphatic Filariasis Infection: A Cross-sectional Study in Rural Northern Malawi Tafatatha, Terence Taegtmeyer, Miriam Ngwira, Bagrey Phiri, Amos Kondowe, Mariot Piston, Wilson Molesworth, Anna Kayuni, Ndoliwe Koole, Olivier Crampin, Amelia Horton, John French, Neil PLoS Negl Trop Dis Research Article BACKGROUND: Lymphatic filariasis (LF) and human immunodeficiency virus (HIV) are major public health problems. Individuals may be co-infected, raising the possibility of important interactions between these two pathogens with consequences for LF elimination through annual mass drug administration (MDA). METHODOLOGY AND PRINCIPAL FINDINGS: We analysed circulating filarial antigenaemia (CFA) by HIV infection status among adults in two sites in northern Malawi, a region endemic for both LF and HIV. Stored blood samples and data from two geographically separate studies were used: one a recruitment phase of a clinical trial of anti-filarial agent dosing regimens, and the other a whole population annual HIV sero-survey. In study one, 1,851 consecutive adult volunteers were screened for HIV and LF infection. CFA prevalence was 25.4% (43/169) in HIV-positive and 23.6% (351/1487) in HIV-negative participants (p=0.57). Geometric mean CFA concentrations were 859 and 1660 antigen units per ml of blood (Ag/ml) respectively, geometric mean ratio (GMR) 0.85, 95%CI 0.49-1.50. In 7,863 adults in study two, CFA prevalence was 20.9% (86/411) in HIV-positive and 24.0% (1789/7452) in HIV–negative participants (p=0.15). Geometric mean CFA concentrations were 630 and 839 Ag/ml respectively (GMR 0.75, 95%CI 0.60-0.94). In the HIV-positive group, antiretroviral therapy (ART) use was associated with a lower CFA prevalence, 12.7% (18/142) vs. 25.3% (67/265), (OR 0.43, 95%CI 0.24-0.76). Prevalence of CFA decreased with duration of ART use, 15.2% 0-1 year (n=59), 13.6% >1-2 years (n=44), 10.0% >2-3 years (n=30) and 0% >3-4 years treatment (n=9), p<0.01 χ(2) for linear trend. CONCLUSIONS/SIGNIFICANCE: In this large cross-sectional study of two distinct LF-exposed populations, there is no evidence that HIV infection has an impact on LF epidemiology that will interfere with LF control measures. A significant association of ART use with lower CFA prevalence merits further investigation to understand this apparent beneficial impact of ART. Public Library of Science 2015-06-04 /pmc/articles/PMC4456405/ /pubmed/26042839 http://dx.doi.org/10.1371/journal.pntd.0003825 Text en © 2015 Tafatatha et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Tafatatha, Terence
Taegtmeyer, Miriam
Ngwira, Bagrey
Phiri, Amos
Kondowe, Mariot
Piston, Wilson
Molesworth, Anna
Kayuni, Ndoliwe
Koole, Olivier
Crampin, Amelia
Horton, John
French, Neil
Human Immunodeficiency Virus, Antiretroviral Therapy and Markers of Lymphatic Filariasis Infection: A Cross-sectional Study in Rural Northern Malawi
title Human Immunodeficiency Virus, Antiretroviral Therapy and Markers of Lymphatic Filariasis Infection: A Cross-sectional Study in Rural Northern Malawi
title_full Human Immunodeficiency Virus, Antiretroviral Therapy and Markers of Lymphatic Filariasis Infection: A Cross-sectional Study in Rural Northern Malawi
title_fullStr Human Immunodeficiency Virus, Antiretroviral Therapy and Markers of Lymphatic Filariasis Infection: A Cross-sectional Study in Rural Northern Malawi
title_full_unstemmed Human Immunodeficiency Virus, Antiretroviral Therapy and Markers of Lymphatic Filariasis Infection: A Cross-sectional Study in Rural Northern Malawi
title_short Human Immunodeficiency Virus, Antiretroviral Therapy and Markers of Lymphatic Filariasis Infection: A Cross-sectional Study in Rural Northern Malawi
title_sort human immunodeficiency virus, antiretroviral therapy and markers of lymphatic filariasis infection: a cross-sectional study in rural northern malawi
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456405/
https://www.ncbi.nlm.nih.gov/pubmed/26042839
http://dx.doi.org/10.1371/journal.pntd.0003825
work_keys_str_mv AT tafatathaterence humanimmunodeficiencyvirusantiretroviraltherapyandmarkersoflymphaticfilariasisinfectionacrosssectionalstudyinruralnorthernmalawi
AT taegtmeyermiriam humanimmunodeficiencyvirusantiretroviraltherapyandmarkersoflymphaticfilariasisinfectionacrosssectionalstudyinruralnorthernmalawi
AT ngwirabagrey humanimmunodeficiencyvirusantiretroviraltherapyandmarkersoflymphaticfilariasisinfectionacrosssectionalstudyinruralnorthernmalawi
AT phiriamos humanimmunodeficiencyvirusantiretroviraltherapyandmarkersoflymphaticfilariasisinfectionacrosssectionalstudyinruralnorthernmalawi
AT kondowemariot humanimmunodeficiencyvirusantiretroviraltherapyandmarkersoflymphaticfilariasisinfectionacrosssectionalstudyinruralnorthernmalawi
AT pistonwilson humanimmunodeficiencyvirusantiretroviraltherapyandmarkersoflymphaticfilariasisinfectionacrosssectionalstudyinruralnorthernmalawi
AT molesworthanna humanimmunodeficiencyvirusantiretroviraltherapyandmarkersoflymphaticfilariasisinfectionacrosssectionalstudyinruralnorthernmalawi
AT kayunindoliwe humanimmunodeficiencyvirusantiretroviraltherapyandmarkersoflymphaticfilariasisinfectionacrosssectionalstudyinruralnorthernmalawi
AT kooleolivier humanimmunodeficiencyvirusantiretroviraltherapyandmarkersoflymphaticfilariasisinfectionacrosssectionalstudyinruralnorthernmalawi
AT crampinamelia humanimmunodeficiencyvirusantiretroviraltherapyandmarkersoflymphaticfilariasisinfectionacrosssectionalstudyinruralnorthernmalawi
AT hortonjohn humanimmunodeficiencyvirusantiretroviraltherapyandmarkersoflymphaticfilariasisinfectionacrosssectionalstudyinruralnorthernmalawi
AT frenchneil humanimmunodeficiencyvirusantiretroviraltherapyandmarkersoflymphaticfilariasisinfectionacrosssectionalstudyinruralnorthernmalawi